Biotechnology Companies in the News – May 2012

Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to email their news releases to BioNJ.

May 15
Former Pro Football Coach Bill Cowher Teams Up With Leading Advocacy Groups to Launch Melanoma Exposed™, an Educational Campaign to Raise Awareness of the Most Deadly Form of Skin Cancer

Celldex Therapeutics Added to Nasdaq Biotechnology Index

Antares Pharma Appoints LeRoux Jooste Senior Vice President Pharmaceutical Sales and Marketing

Derma Sciences Reports First Quarter 2012 Financial Results

Advaxis Retires $4.5 Million in Debt, Adds $1,240,000 in New Financing

Senesco Technologies Reports Fiscal 2012 Third Quarter Results

May 14
Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments

Cyclacel Reports First Quarter 2012 Financial Results

Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2/3 Randomized Trial Comparing Sapacitabine to Low Dose Cytarabine

Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership

Bristol-Myers Squibb to Present New Data on ORENCIA® (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress

May 11
Arno Therapeutics Announces Orphan-Drug Designation for AR-42 in Europe

Derma Sciences to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

Paragon Sponsors CBI Conference on Electronic Trial Master File Implementation

May 10
Onconova Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes

Antares Pharma to Present at the 15th Annual Bank of America Merrill Lynch Health Care Conference

Amicus Therapeutics Announces First Quarter 2012 Financial Results

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Health Care Conference

New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma

May 9
DSP Clinical Named to Prestigious List of Top 50 Fastest-Growing Women-Owned Companies in North America

May 8
Cyclacel Pharmaceuticals to Announce Release of First Quarter 2012 Financial Results

Immunomedics Announces Third Quarter Fiscal 2012 Results and Clinical Program Developments

Antares Pharma Reports First Quarter 2012 Financial and Operating Results

Merck to Present at Deutsche Bank 37th Annual Health Care Conference

GE Healthcare Secures Additional Supply of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)

The Medicines Company to Participate in Bank of America Merrill Lynch 2012 Healthcare Conference

May 7
Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel

Global Life Science hiring increases nearly 4% during Q1 2012

Unigene Announces First Quarter 2012 Financial Results

May 4
Columbia Laboratories Reports First Quarter 2012 Financial Results

Celgene Corporation to Present at Two Upcoming Investor Conferences

May 3
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes

Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 First Quarter Results

NPS Pharmaceuticals Reports Four Additional Patients Achieve Independence from Parenteral Support in STEPS 2 Study of Gattex® in Adult Short Bowel Syndrome

Celldex Reports First Quarter 2012 Financial Results

NPS Pharmaceuticals Reports First Quarter 2012 Financial Results

May 2
Aegerion Pharmaceuticals Announces Participation at Deutsche Bank and Bank of America Merrill Lynch Healthcare Conferences

Enzon Reports First Quarter 2012 Results

Kevin C. O’Boyle Joins Durata Therapeutics’ Board of Directors

Lexicon Receives Funding for Phase 2 Clinical Trial of Lx4211 in Type 1 Diabetes

May 1
Celldex Announces Plans to Release Topline Results from the EMERGE Study in Advanced Breast Cancer

Immunomedics Awarded New Patent for Pretargeted Imaging and Therapy of Cancer with Bispecific Antibody

Aegerion Pharmaceuticals Announces First Quarter 2012 Financial Results

Antares Pharma to Host First Quarter 2012 Earnings Call

Advaxis Research Accepted for American Association of Immunologists Annual Meeting, Demonstrates Reduction of Tumor Defenses

Combination of Lenalidomide and SNS01-T Effective in Cancer Model

April 30
Aegerion Pharmaceuticals Announces FDA Acceptance of New Drug Application for Review

Bristol-Myers Squibb to Present at Deutsche Bank Health Care Conference

Strength of Aptalis Pharmaceutical Technologies Patents Confirmed by AMRIX® Verdict

April 27
NPS Pharmaceuticals to Report First Quarter 2012 Financial Results

Novo Nordisk Plans 15 Percent Expansion of U.S. Work Force in 2012

April 26
Announcement of the 1st Quarter Report 2012

NPS Pharmaceuticals Among 100 Best Places to Work in New Jersey

Merck Wins U.S. ZETIA® (ezetimibe)/ VYTORIN®(ezetimibe/simvastatin) Patent Infringement Lawsuit

Merck Presents Results of a Phase I Clinical Trial Evaluating Investigational BACE inhibitor MK-8931 at American Academy of Neurology

Merck Announces First-Quarter 2012 Financial Results

Antares Pharma Announces Epinephrine Auto-Injector Settlement Agreement Between Teva and Pfizer

Watson and Antares Announce the Introduction of Gelnique 3%™ for the Treatment of Overactive Bladder

Bristol-Myers Squibb Delivers a Solid First Quarter with strong Operating Results and Key R&D Milestones

Celgene Reports First Quarter 2012 Operating and Financial Results

April 25
Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ)

Senator Bob Menendez Honored as BIO Legislator of the Year

Advaxis to Speak at 2012 World Immunotherapy Online Symposium

Recipients of 2012 SAFE-BioPharma “Digi” Awards Named

Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability

AstraZeneca and The Medicines Company Announce Global Collaboration in Acute Ischemic Heart Disease

Lexicon to Provide First Quarter 2012 Financial Results

The Medicines Company Reports First Quarter 2012 Financial Results

April 24
MicroDose Therapeutx Announces Conclusion of MDT-637 Phase I Single and Multiple Ascending Dose Studies in Healthy Volunteers for Treatment of Respiratory Syncytial Virus (RSV)

Columbia Laboratories to Discuss First Quarter 2012 Financial Results on May 4 Conference Call

April 23
Ezose Sciences and Hirosaki University to Collaborate in Glycomics Research to Find New Cancer Biomarkers

Photocure Launches New Corporate Website

April 20
Circuite® Provides Updated Clinical Data on Synergy® Miniature Ventricular Support System in Multiple Presentations at ISHLT Annual Meeting

April 19
All-Oral Combination of Investigational Hepatitis C (HCV) Compounds Daclatasvir and GS-7977 Achieved Sustained Virologic Response (SVR4) in 100% of Genotype 1 and 91% of Genotype 2 and 3 Treatment-Naïve Patients in Phase II Study

Merck Reports Phase III Study Results Evaluating Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy

Orphan Drug Designation Granted to SK Biopharmaceuticals’ Carisbamate for the Management of Infantile Spasms

OPUS Health, a Division of Cegedim Relationship Management, Now Delivers Medication Loyalty and Adherence Solutions via e-Prescribing Systems

April 18
Merck Wins Another FOSAMAX® (alendronate sodium) State Court Trial

April 17
Cyclacel Pharmaceuticals Announces Grant of New U.S. Patent Covering Sapacitabine

“What Every Mama Needs To Know About Cord Blood Banking”

Celgene Corporation to Announce First Quarter 2012 Results on April 26, 2012

Decision Resources Group Acquires Pinsonault

Bristol-Myers Squibb Ranks First on 2012 Best Corporate Citizens List

April 16
Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)

Amicus Therapeutics Names William D. Baird, III Chief Financial Officer

Nascent and Catalent Sign Cancer Antibody Development Deal